» Articles » PMID: 32371789

Impact of Single-pill Combination Therapy on Adherence, Blood Pressure Control, and Clinical Outcomes: a Rapid Evidence Assessment of Recent Literature

Overview
Journal J Hypertens
Date 2020 May 7
PMID 32371789
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The 2018 European Society of Cardiology/European Society of Hypertension Guidelines for the management of arterial hypertension raised the need for evidence to support the use of single-pill combination (SPC) therapy in preference to free-dosed therapy for hypertension. This systematic rapid evidence assessment sought to determine if initiating SPC therapy improves adherence, blood pressure (BP) control and/or cardiovascular outcomes vs. initiation of free-dose combination therapy.

Methods: Rapid evidence assessment conducted in MEDLINE, EMBASE, and Cochrane Library (1 January 2013-11 January 2019) to identify studies investigating SPC therapy for adults with hypertension. Information on adherence/persistence, BP lowering/goal attainment, and cardiovascular outcomes/events were extracted via two-phase screening process. Studies not focusing on adherence, persistence, or compliance with SPC therapy were excluded. Methodological quality was assessed using appropriate scales.

Results: Of 863 citations, 752 failed to meet inclusion or were duplicates. Twenty-nine studies remained following full-text screening. Just four studies (14%) were randomized controlled studies; 25 (86%) were observational. A range of SPC therapies were studied, with calcium channel blocker/angiotensin receptor blocker combinations most common (11/29 studies). Adherence and persistence were generally higher with SPC vs. free-dose combination therapy; 15 studies (54%) directly compared adherence and four (14%) compared persistence. Patients achieving BP targets ranged from 25 to 89%. Despite all studies investigating patients with hypertension only 16 (55%) reported change in BP. Few studies reported on cardiovascular outcomes. Methodological reporting was often suboptimal.

Conclusion: Adherence and/or persistence were generally higher in patients taking antihypertensives as SPC vs. free-dose combination; however, methodological reporting was suboptimal to facilitate comparison. Specifically designed, well reported studies are required to determine if the increased adherence/persistence seen in patients on SPC regimen leads to improved BP control and/or cardiovascular outcomes.

Citing Articles

Novel pharmacological approaches to lowering blood pressure and managing hypertension.

Sayer M, Webb D, Dhaun N Nat Rev Cardiol. 2025; .

PMID: 39920248 DOI: 10.1038/s41569-025-01131-4.


Systemic hypertension in adults with congenital heart diseases.

Sabatino J, Avesani M, Sirico D, Reffo E, Castaldi B, Bassareo P Int J Cardiol Congenit Heart Dis. 2024; 13:100456.

PMID: 39712235 PMC: 11658137. DOI: 10.1016/j.ijcchd.2023.100456.


Effect of single-pill versus free equivalent combinations on persistence and major adverse cardiovascular events in hypertension: a real-world analysis.

Simonyi G, Burnier M, Narkiewicz K, Rokszin G, Abonyi-Toth Z, Kovacs G J Hypertens. 2024; 43(3):405-412.

PMID: 39641301 PMC: 11789606. DOI: 10.1097/HJH.0000000000003916.


Prevalence, Clinical Characteristics, and Treatment of Patients with Resistant Hypertension: A Single-Center Study.

Naydenov S, Manov E, Runev N J Cardiovasc Dev Dis. 2024; 11(9).

PMID: 39330337 PMC: 11432305. DOI: 10.3390/jcdd11090279.


The Pathophysiology, Prognosis and Treatment of Hypertension in Females from Pregnancy to Post-menopause: A Review.

Li S, Tan I, Atkins E, Schutte A, Gnanenthiran S Curr Heart Fail Rep. 2024; 21(4):322-336.

PMID: 38861130 PMC: 11333539. DOI: 10.1007/s11897-024-00672-y.


References
1.
Czarnecka D, Koch E, Gottwald-Hostalek U . Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. Curr Med Res Opin. 2015; 31(5):875-81. DOI: 10.1185/03007995.2015.1027676. View

2.
Vrijens B, Antoniou S, Burnier M, De La Sierra A, Volpe M . Current Situation of Medication Adherence in Hypertension. Front Pharmacol. 2017; 8:100. PMC: 5331678. DOI: 10.3389/fphar.2017.00100. View

3.
Fleig S, Weger B, Haller H, Limbourg F . Effectiveness of a Fixed-Dose, Single-Pill Combination of Perindopril and Amlodipine in Patients with Hypertension: A Non-Interventional Study. Adv Ther. 2018; 35(3):353-366. PMC: 5859137. DOI: 10.1007/s12325-018-0675-3. View

4.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M . 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7):1281-357. DOI: 10.1097/01.hjh.0000431740.32696.cc. View

5.
Geldsetzer P, Manne-Goehler J, Marcus M, Ebert C, Zhumadilov Z, Wesseh C . The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. Lancet. 2019; 394(10199):652-662. DOI: 10.1016/S0140-6736(19)30955-9. View